{"id":483062,"date":"2021-04-28T07:04:31","date_gmt":"2021-04-28T11:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/"},"modified":"2021-04-28T07:04:31","modified_gmt":"2021-04-28T11:04:31","slug":"foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/","title":{"rendered":"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., April  28, 2021  (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27.<\/p>\n<p align=\"justify\">\u201cIan is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company\u2019s evolution,\u201d stated Adrian Gottschalk, Foghorn\u2019s Chief Executive Officer. \u201cIan has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings significant business experience and capital formation expertise to our Company.\u201d<\/p>\n<p align=\"justify\">\u201cI believe in a precision biology approach that focuses on the cause of disease; Foghorn\u2019s focus on the chromatin regulatory system and its causal role in a broad range of serious diseases has the potential to create significant therapeutic breakthroughs,\u201d stated Mr. Smith. \u201cI am pleased to join the Board and look forward to working with my fellow Board members, Adrian and the Foghorn leadership team.\u201d<\/p>\n<p>\u201cWe welcome Ian to the Foghorn Board,\u201d stated Doug Cole, MD, Chairman of Foghorn\u2019s Board of Directors. \u201cHis experience building valuable biotech businesses will help us to deliver on the enormous potential of drugs based on chromatin dysregulation.\u201d<\/p>\n<p align=\"justify\">Mr. Smith is currently the Executive Chairperson of Viacyte, Inc. He was previously Chief Operating Officer at Vertex Pharmaceuticals, Inc. Prior to joining Vertex in 2001, Mr. Smith served as a partner in the Life Science and Technology Practice of the accounting firm Ernst &amp; Young LLP. He also serves as Chairman of the Board of Solid Biosciences, as a board member of AavantiBio Inc., and as a Senior Advisor to Bain Capital Life Sciences.<\/p>\n<p align=\"justify\">\n        <strong>About Foghorn Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Foghorn<sup>\u00ae<\/sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>\u00ae<\/sup> platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d regarding the Company\u2019s approach to treating disease. Forward-Forward-looking statements include statements regarding the Company\u2019s clinical trial, product candidates and research efforts and other statements identified by words such as \u201ccould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201clikely,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201ccontinues,\u201d \u201cprojects\u201d and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of filing an IND for our product candidates and other factors set forth under the heading \u201cRisk Factors\u201d in the Company\u2019s Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.<\/p>\n<p>\n        <strong>Media Contact: <\/strong>\n      <\/p>\n<p>Fanny Cavali\u00e9, Foghorn Therapeutics <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cjm95Vcm2c5a3C5zkVWpMZ3hIGTqVPY0Q0-ACtca1PkW7BnDQSSjQbjujBYZotzNh8DwexLH4CpgWmYH40kIN7JwdvH00B3kjwZpUju3EVU=\" rel=\"nofollow noopener\" target=\"_blank\">fcavalie@foghorntx.com<\/a><\/p>\n<p>Gregory Kelley, Ogilvy <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yvoc_aIElxcScTYjzcEf-KsSbygVfTBlrQibqtN0Vvh6c0dvxX44K5WpJkIFNMmrKfCp6Eow0wGXsLksVSMCkCy3tc-lefdIt6XEZUk4J3k=\" rel=\"nofollow noopener\" target=\"_blank\">gregory.kelley@ogilvy.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact: <\/strong>\n      <\/p>\n<p>Allan Reine, Foghorn Therapeutics <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vT_6wm7aSpqtt4FoONV1uiSXAGrPb5GKnO9V6DuDxfKOHaQjTkcAfubSktpwGtnsKCGWMi6peocNgFVWKq6sPfOmmaq-GifIcAQheswWA_Y=\" rel=\"nofollow noopener\" target=\"_blank\">areine@foghorntx.com<\/a><\/p>\n<p>Hans Vitzthun, LifeSci Advisors<br \/>617-535-7743<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SBasLNQ0xFtc-e1050I18CSpuYemhRAb2ghw0Yw0XT46IasTrSIxn5nbWKeFI7a8kcjP_AXYe4Gb6mPK5Ylc3P4KydBytddtXyo8nLxMpqM=\" rel=\"nofollow noopener\" target=\"_blank\">hans@lifesciadvisors.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/eb72d4b9-a0ad-4fb5-a192-02ed50c1ad2f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27. \u201cIan is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company\u2019s evolution,\u201d stated Adrian Gottschalk, Foghorn\u2019s Chief Executive Officer. \u201cIan has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics Appoints Ian Smith to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-483062","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics Appoints Ian Smith to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27. \u201cIan is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company\u2019s evolution,\u201d stated Adrian Gottschalk, Foghorn\u2019s Chief Executive Officer. \u201cIan has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings &hellip; Continue reading &quot;Foghorn Therapeutics Appoints Ian Smith to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T11:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors\",\"datePublished\":\"2021-04-28T11:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/\"},\"wordCount\":607,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/\",\"name\":\"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=\",\"datePublished\":\"2021-04-28T11:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27. \u201cIan is a proven biotechnology leader with a diverse skill set, and I am excited to welcome him to our Board at this important time in the company\u2019s evolution,\u201d stated Adrian Gottschalk, Foghorn\u2019s Chief Executive Officer. \u201cIan has been advising the company since early 2020 on various initiatives including business development and equity financing strategies as well as company progression and development. The addition of Ian to our Board brings &hellip; Continue reading \"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-28T11:04:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors","datePublished":"2021-04-28T11:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/"},"wordCount":607,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/","name":"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=","datePublished":"2021-04-28T11:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTEyNyM0MTQzMTUyIzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-appoints-ian-smith-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics Appoints Ian Smith to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=483062"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/483062\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=483062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=483062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=483062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}